Press Releases

July 23 2012

Groups issue booklet to help biotechnology and pharmaceutical companies identify pipeline...

June 28 2011

BIO announced its endorsement of the “Joint Declaration on Cooperation in the Fight...

January 3 2011

The 2011 BIO International Convention will highlight the latest trends and the newest...

May 4 2010

A new report issued by the Biotechnology Industry Organization underscores how biotechnology...

November 12 1998

Carl B Feldbaum, president of  BIO, today issued the following statement on the need for...

April 22 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the Request for Information (RFI) on “Standards for the Interoperable Exchange of Information for Tracing of Human, Finished, Prescription Drugs, in Paper or Electronic Format.”
March 4 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Request for Nominations: Drug Products that Present Demonstrable Difficulties for Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.”
February 3 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Draft Guidance for Industry on Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act.”
January 22 2014
On behalf of the member companies of Biotechnology Industry Organization (BIO), we respectfully request that the Office of Management and Budget (OMB) issue the proposed Food and Drug Administration (FDA) regulation on the electronic distribution of prescribing information for human drugs and biologics. Once implemented, the rule will provide patients, providers, and caregivers with timely access to the most up-to-date prescribing information to inform the safe use of FDA-approved therapies.
January 3 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Proposed Rule: Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products.”
May 24 2013
Rx Response elevates to Alert status to address potential impact from Moore tornado on supply chain.
July 23 2012
Groups issue booklet to help biotechnology and pharmaceutical companies identify pipeline medicines with doping potential.
June 28 2011
BIO announced its endorsement of the “Joint Declaration on Cooperation in the Fight against Doping in Sport” between the World Anti-Doping Agency (WADA) and the International Federation of Pharmaceutical Manufactures and Associations (IFPMA).
January 3 2011
The 2011 BIO International Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world.